The National Institute of Diabetes & Digestive & Kidney Diseases

Pharmacogenomics and Personalized Medicine in the Treatment of Diabetes Program

The Pharmacogenomics and Personalized Medicine in the Treatment of Diabetes Program supports projects that focus on increasing our understanding of the genetic and epigenetic variation that influences the effectiveness and safety of pharmacotherapy for diabetes and related disorders.  This program also supports efforts to translate these and other findings into clinical practice and to develop technologies to support these efforts.  Areas of interest include, but are not limited to:

a) Use of genetic analysis such as genome-wide association studies, copy-number variation determination, fine-mapping, and functional genomics to identify genes and epigenetic factors that contribute to variable responses to drugs.

b) Studies to understand the contributions and mechanisms of genetic and epigenetic variation, as well as other forms of variation, by examining their functional consequences in the pharmacodynamic and pharmacokinetic responses to and of therapeutic agents.

c) Development of new experimental and computational methodologies, platforms, and models to facilitate the understanding of pharmacologically-relevant genetic and epigenetic variation within populations and individuals.

d) Formation of collaborative relationships between basic scientists, clinicians, geneticists, computational biologists, regulatory affairs experts, and industry to translate discoveries into practical approaches to personalized medicine.

For more information, contact Dr. Aaron Pawlyk, Director, Pharmacogenomics.

Page last updated: March 25, 2011